LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 5 of total 5

Search options

  1. Article ; Online: Role of protective stoma after primary anastomosis for generalized peritonitis due to perforated diverticulitis-DIVERTI 2 (a prospective multicenter randomized trial): rationale and design (nct04604730).

    Pinson, Jean / Tuech, Jean-Jacques / Ouaissi, Mehdi / Mathonnet, Murielle / Mauvais, François / Houivet, Estelle / Lacroix, Elie / Rondeaux, Julie / Sabbagh, Charles / Bridoux, Valérie

    BMC surgery

    2022  Volume 22, Issue 1, Page(s) 191

    Abstract: Background: Traditionally, patients with peritonitis Hinchey III and IV due to perforated diverticulitis were treated with Hartmann's procedure. In the past decade, resection and primary anastomosis have gained popularity over Hartmann's procedure and ... ...

    Abstract Background: Traditionally, patients with peritonitis Hinchey III and IV due to perforated diverticulitis were treated with Hartmann's procedure. In the past decade, resection and primary anastomosis have gained popularity over Hartmann's procedure and recent guidelines recommend Hartmann's procedure in two situations only: critically ill patients and in selected patients with multiple comorbidity (at high risk of complications). The protective stoma (PS) is recommended after resection with primary anastomosis, however its interest has never been studied. The aim of this trial is to define the role of systematic PS after resection and primary anastomosis for peritonitis Hinchey III and IV due to perforated diverticulitis.
    Methods/design: This DIVERTI 2 trial is a multicenter, randomized, controlled, superiority trial comparing resection and primary anastomosis with (control group) or without (experimental group) PS in patients with peritonitis Hinchey III and IV due to perforated diverticulitis. Primary endpoint is the overall 1 year morbidity according to the Clavien-Dindo classification of surgical complications. All complications occurring during hospitalization will be collected. Late complications occurring after hospitalization will be collected during follow-up. In order to obtain 80% power for a difference given by respective main probabilities of 67% and 47% in the protective stoma and no protective stoma groups respectively, with a two-sided type I error of 5%, 96 patients will have to be included in each group, hence 192 patients overall. Expecting a 5% rate of patients not assessable for the primary end point (lost to follow-up), 204 patients will be enrolled. Secondary endpoints are postoperative mortality, unplanned reinterventions, incisional surgical site infection (SSI), organ/space SSI, wound disruption, anastomotic leak, operating time, length of hospital stay, stoma at 1 year after initial surgery, quality of life, costs and quality-adjusted life years (QALYs).
    Discussion: The DIVERTI 2 trial is a prospective, multicenter, randomized, study to define the best strategy between PS and no PS in resection and primary anastomosis for patients presenting with peritonitis due to perforated diverticulitis.
    Trial registration: ClinicalTrial.gov: NCT04604730 date of registration October 27, 2020. https://clinicaltrials.gov/ct2/show/NCT04604730?recrs=a&cond=Diverticulitis&draw=2&rank=12 .
    MeSH term(s) Anastomosis, Surgical/adverse effects ; Colostomy/adverse effects ; Diverticulitis/complications ; Diverticulitis/surgery ; Diverticulitis, Colonic/complications ; Diverticulitis, Colonic/surgery ; Humans ; Intestinal Perforation/complications ; Intestinal Perforation/surgery ; Peritonitis/complications ; Peritonitis/surgery ; Prospective Studies ; Quality of Life ; Treatment Outcome
    Language English
    Publishing date 2022-05-16
    Publishing country England
    Document type Journal Article ; Multicenter Study ; Randomized Controlled Trial
    ZDB-ID 2050442-1
    ISSN 1471-2482 ; 1471-2482
    ISSN (online) 1471-2482
    ISSN 1471-2482
    DOI 10.1186/s12893-022-01589-w
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article ; Online: Multicenter phase III randomized trial comparing laparoscopy and laparotomy for colon cancer surgery in patients older than 75 years: the CELL study, a Fédération de Recherche en Chirurgie (FRENCH) trial.

    Manceau, Gilles / Brouquet, Antoine / Chaibi, Pascal / Passot, Guillaume / Bouché, Olivier / Mathonnet, Murielle / Regimbeau, Jean-Marc / Lo Dico, Rea / Lefèvre, Jérémie H / Peschaud, Frédérique / Facy, Olivier / Volpin, Enrico / Chouillard, Elie / Beyert-Berjot, Laura / Verny, Marc / Karoui, Mehdi / Benoist, Stéphane

    BMC cancer

    2019  Volume 19, Issue 1, Page(s) 1185

    Abstract: Background: Several multicenter randomized controlled trials comparing laparoscopy and conventional open surgery for colon cancer have demonstrated that laparoscopic approach achieved the same oncological results while improving significantly early ... ...

    Abstract Background: Several multicenter randomized controlled trials comparing laparoscopy and conventional open surgery for colon cancer have demonstrated that laparoscopic approach achieved the same oncological results while improving significantly early postoperative outcomes. These trials included few elderly patients, with a median age not exceeding 71 years. However, colon cancer is a disease of the elderly. More than 65% of patients operated on for colon cancer belong to this age group, and this proportion may become more pronounced in the coming years. In current practice, laparoscopy is underused in this population.
    Methods: The CELL (Colectomy for cancer in the Elderly by Laparoscopy or Laparotomy) trial is a multicenter, open-label randomized, 2-arm phase III superiority trial. Patients aged 75 years or older with uncomplicated colonic adenocarcinoma or endoscopically unresectable colonic polyp will be randomized to either colectomy by laparoscopy or laparotomy. The primary endpoint of the study is overall postoperative morbidity, defined as any complication classification occurring up to 30 days after surgery. The secondary endpoints are: 30-day and 90-day postoperative mortality, 30-day readmission rate, quality of surgical resection, health-related quality of life and evolution of geriatric assessment. A 35 to 20% overall postoperative morbidity rate reduction is expected for patients operated on by laparoscopy compared with those who underwent surgery by laparotomy. With a two-sided α risk of 5% and a power of 80% (β = 0.20), 276 patients will be required in total.
    Discussion: To date, no dedicated randomized controlled trial has been conducted to evaluate morbidity after colon cancer surgery by laparoscopy or laparotomy in the elderly and the benefits of laparoscopy is still debated in this context. Thus, a prospective multicenter randomized trial evaluating postoperative outcomes specifically in elderly patients operated on for colon cancer by laparoscopy or laparotomy with curative intent is warranted. If significant, such a study might change the current surgical practices and allow a significant improvement in the surgical management of this population, which will be the vast majority of patients treated for colon cancer in the coming years.
    Trial registration: ClinicalTrials.gov NCT03033719 (January 27, 2017).
    MeSH term(s) Aged ; Aged, 80 and over ; Clinical Trials, Phase III as Topic ; Colectomy/adverse effects ; Colectomy/methods ; Colonic Neoplasms/pathology ; Colonic Neoplasms/surgery ; Geriatric Assessment ; Humans ; Laparoscopy ; Laparotomy ; Postoperative Complications/epidemiology ; Quality of Life ; Randomized Controlled Trials as Topic
    Language English
    Publishing date 2019-12-04
    Publishing country England
    Document type Clinical Trial Protocol ; Journal Article
    ISSN 1471-2407
    ISSN (online) 1471-2407
    DOI 10.1186/s12885-019-6376-8
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article ; Online: Is the 2-cm size cutoff relevant for small nonfunctioning pancreatic neuroendocrine tumors: A French multicenter study.

    Regenet, Nicolas / Carrere, Nicolas / Boulanger, Guillaume / de Calan, Loic / Humeau, Marine / Arnault, Vincent / Kraimps, Jean-Louis / Mathonnet, Murielle / Pessaux, Patrick / Donatini, Gianluca / Venara, Aurelien / Christou, Niki / Bachelier, Philippe / Hamy, Antoine / Mirallié, Eric

    Surgery

    2016  Volume 159, Issue 3, Page(s) 901–907

    Abstract: Background: Nonfunctioning pancreatic neuroendocrine tumors (NF-PNETs) are often discovered at a small size. No clear consensus exists on the management of NF-PNETs ≤ 2 cm. The aim of our study was to determine the prognostic value of indicators of ... ...

    Abstract Background: Nonfunctioning pancreatic neuroendocrine tumors (NF-PNETs) are often discovered at a small size. No clear consensus exists on the management of NF-PNETs ≤ 2 cm. The aim of our study was to determine the prognostic value of indicators of malignancy in sporadic NF-PNETs ≤ 2 cm.
    Methods: Eighty patients were evaluated retrospectively in 7 French University Hospital Centers. Patients were managed by operative resection (operative group [OG]) or observational follow-up (non-OG [NOG]). Pathologic characteristics and outcomes were analyzed.
    Results: Sixty-six patients (58% women) were in the OG (mean age, 59 years; 95% CI, 56.0-62.3; mean tumor size, 1.6 cm; 95% CI, 1.5-1.7); 14 (72% women, n = 10) were in the NOG (mean age, 63 years; 95% CI, 56-70; mean tumor size, 1.4 cm; 95% CI, 1.0-1.7). All PNETs were ranked using the European Neuroendocrine Tumor Society grading system. Fifteen patients (19%) had malignant tumors defined by node or liver metastasis (synchronous or metachronous). The median disease-free survival was different between malignant and nonmalignant PNETs, respectively: 16 (range, 4-72) versus 30 months (range, 1-156; P = .03). On a receiver operating characteristic (ROC) curve, tumor size had a significant impact on malignancy (area under the curve [AUC], 0.75; P = .03), but not Ki-67 (AUC, 0.59; P = .31). A tumor size cutoff was found on the ROC curve at 1.7 cm (odd ratio, 10.8; 95% CI; 2.2-53.2; P = .003) with a sensitivity of 92% and a specificity of 75% to predict malignancy.
    Conclusion: Based on our retrospective study, the cutoff of 2 cm of malignancy used for small NF-PNETs could be decreased to 1.7 cm to select patients more accurately.
    MeSH term(s) Aged ; Cohort Studies ; Disease-Free Survival ; Endosonography/methods ; Female ; Follow-Up Studies ; France ; Humans ; Incidental Findings ; Kaplan-Meier Estimate ; Magnetic Resonance Imaging/methods ; Male ; Middle Aged ; Multimodal Imaging/methods ; Neoplasm Invasiveness/pathology ; Neoplasm Staging ; Pancreatectomy/methods ; Pancreatectomy/mortality ; Pancreatic Neoplasms/diagnosis ; Pancreatic Neoplasms/mortality ; Pancreatic Neoplasms/pathology ; Pancreatic Neoplasms/surgery ; Positron-Emission Tomography/methods ; ROC Curve ; Retrospective Studies ; Risk Assessment ; Statistics, Nonparametric ; Survival Analysis ; Treatment Outcome ; Tumor Burden
    Language English
    Publishing date 2016-03
    Publishing country United States
    Document type Journal Article ; Multicenter Study
    ZDB-ID 202467-6
    ISSN 1532-7361 ; 0039-6060
    ISSN (online) 1532-7361
    ISSN 0039-6060
    DOI 10.1016/j.surg.2015.10.003
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article: Embolization of rectal arteries: an alternative treatment for hemorrhagic shock induced by traumatic intrarectal hemorrhage.

    Pichon, Nicolas / François, Bruno / Pichon-Lefièvre, Florence / Mathonnet, Murielle / Maubon, Antoine / Vignon, Philippe

    Cardiovascular and interventional radiology

    2005  Volume 28, Issue 4, Page(s) 515–517

    Abstract: Rectal injuries caused by foreign bodies or iatrogenic insertions may lead to severe complications whose therapeutic management remains controversial. At times, both the rapid identification and treatment of subsequent active rectal bleeding may be ... ...

    Abstract Rectal injuries caused by foreign bodies or iatrogenic insertions may lead to severe complications whose therapeutic management remains controversial. At times, both the rapid identification and treatment of subsequent active rectal bleeding may be challenging, especially when endoscopy fails to locate and control the arterial hemorrhage. We present the first two successful cases of middle rectal artery embolization in patients presenting with sustained bleeding and hemorrhagic shock.
    MeSH term(s) Embolization, Therapeutic ; Foreign Bodies/complications ; Hemorrhage/diagnostic imaging ; Hemorrhage/etiology ; Hemorrhage/therapy ; Humans ; Male ; Middle Aged ; Rectum/blood supply ; Rectum/diagnostic imaging ; Rectum/injuries ; Shock, Hemorrhagic/diagnostic imaging ; Shock, Hemorrhagic/etiology ; Shock, Hemorrhagic/therapy ; Tomography, X-Ray Computed
    Language English
    Publishing date 2005-07
    Publishing country United States
    Document type Case Reports ; Journal Article
    ZDB-ID 603082-8
    ISSN 1432-086X ; 0174-1551 ; 0342-7196
    ISSN (online) 1432-086X
    ISSN 0174-1551 ; 0342-7196
    DOI 10.1007/s00270-004-0168-4
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Article: Tissue concentrations of platelet-activating factor in colorectal carcinoma: inverse relationships with Dukes' stage of patients.

    Denizot, Yves / Gainant, Alain / Guglielmi, Laurence / Bouvier, Stephane / Cubertafond, Pierre / Mathonnet, Murielle

    Oncogene

    2003  Volume 22, Issue 46, Page(s) 7222–7224

    Abstract: The lipid mediator platelet-activating factor (PAF) plays a role in cancer. We investigated its presence in human colon carcinoma by assessing the levels of tissue phospholipase A(2) (PLA(2), the key enzyme in the generation of the lyso-PAF precursor), ... ...

    Abstract The lipid mediator platelet-activating factor (PAF) plays a role in cancer. We investigated its presence in human colon carcinoma by assessing the levels of tissue phospholipase A(2) (PLA(2), the key enzyme in the generation of the lyso-PAF precursor), lyso-PAF, PAF and acetylhydrolase activity (AHA, the key enzyme in PAF degradation) in colorectal cancer patients and by correlating them with Dukes' classification. The results highlighted that the tumour tissues of Dukes' A and B patients had significantly higher PLA(2), lyso-PAF, PAF and AHA levels as compared with nontumour tissues. Dukes' C patients had higher PLA(2), lyso-PAF and AHA levels but unchanged PAF. Dukes' D patients had higher AHA levels but unchanged PLA(2), lyso-PAF and PAF. A pathophysiological role for PAF is suggested in human colon carcinoma.
    MeSH term(s) 1-Alkyl-2-acetylglycerophosphocholine Esterase/metabolism ; Biomarkers, Tumor/metabolism ; Colonic Neoplasms/pathology ; Colorectal Neoplasms/pathology ; Humans ; Neoplasm Staging ; Phospholipases A/metabolism ; Platelet Activating Factor/analogs & derivatives ; Platelet Activating Factor/metabolism
    Chemical Substances Biomarkers, Tumor ; O-deacetyl platelet activating factor ; Platelet Activating Factor ; Phospholipases A (EC 3.1.1.32) ; 1-Alkyl-2-acetylglycerophosphocholine Esterase (EC 3.1.1.47)
    Language English
    Publishing date 2003-10-16
    Publishing country England
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 639046-8
    ISSN 1476-5594 ; 0950-9232
    ISSN (online) 1476-5594
    ISSN 0950-9232
    DOI 10.1038/sj.onc.1207032
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top